Lv3
390 积分 2020-06-01 加入
Mechanisms of Resistance to Antibody-Drug Conjugates
13天前
已完结
Rare molecular subtypes of lung cancer
1年前
已完结
Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific
1年前
已完结
Pembrolizumab in Combination with Chemotherapy in Patients with ERBB2-Mutated Non-Small Cell Lung Cancer
2年前
已完结
Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC
2年前
已完结
Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors
2年前
已完结
Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease
2年前
已完结
Fusion‐positive non‐small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications
2年前
已完结
A Bayesian network meta-analysis regarding the comparative efficacy of therapeutics for ALK-positive, brain metastatic non-small cell lung cancer
2年前
已完结
Conserved pan-cancer microenvironment subtypes predict response to immunotherapy
2年前
已完结
皖公网安备34019202002308
